Takeda has snapped up US vaccine development company LigoCyte for $60m cash plus possible future earnouts.
Japanese-based drug company, Takeda Pharmaceuticals, has acquired US-based LigoCyte Pharmaceuticals, a developer of vaccines and monoclonal antibodies for gastrointestinal and respiratory diseases. The deal includes a $60m up-front payment and possible earnouts.
LigoCyte has raised more than $30m in funding from Novartis Venture Funds, the Switzerland-based pharmaceutical company’s corporate venturing unit, MedImmune Ventures, the corporate venturing unit of AstraZeneca, Fidelity Biosciences, the venture unit of the asset manager, and venture firms Forward Ventures, JAFCO, Athenian Venture Partners and MC…
